Oestrogen-induced genes in ductal carcinoma in situ: Their comparison with invasive ductal carcinoma

Endocrine-Related Cancer

Volumn 19, Issue 4, 2012, Pages 485-496

  Ebata, Akiko ^a   Suzuki, Takashi ^a   Takagi, Kiyoshi ^a   Miki, Yasuhiro ^a   Onodera, Yoshiaki ^a   Nakamura, Yasuhiro ^a   Fujishima, Fumiyoshi ^b   Ishida, Kazuyuki ^b   Watanabe, Mika ^b   Tamaki, Kentaro ^a   Ishida, Takanori ^a   Ohuchi, Noriaki ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN C MYB; RETINOBLASTOMA BINDING PROTEIN 7; SURVIVIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER TISSUE; CARCINOMA CELL; CLUSTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; ONCOGENE C MYB; PROTEIN MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MICROARRAY ANALYSIS; MIDDLE AGED; UP-REGULATION;

EID: 84864416898     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0345     Document Type: Article

References (57)

1. Al-Joudi FS, Iskandar ZA, Hasnan J, Rusli J, Kamal Y, Imran AK, Ahmed M & Zakaria J 2007 Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast. Singapore Medical Journal 48 607-614.
2. Amari M, Suzuki A, Moriya T, Yoshinaga K, Amano G, Sasano H, Ohuchi N, Satomi S & Horii A 1999 LOH analyses of premalignant and malignant lesions of human breast: frequent LOH in 8p, 16q, and 17q in atypical ductal hyperplasia. Oncology Reports 6 1277-1280.
3. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ & Paesmans M 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. British Journal of Cancer 96 1504-1513. (doi:10.1038/sj.bjc.6603756)
4. Barnes N, Haywood P, Flint P, Knox WF & Bundred NJ 2006 Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. British Journal of Cancer 94 253-258. (doi:10.1038/sj.bjc. 6602932)
5. Bodian CA, Perzin KH, Lattes R & Hoffmann P 1993 Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer 71 3908-3913. (doi:10.1002/1097- 0142(19930615)71:12〈3908::AID-CNCR2820711218〉3.0.CO;2-F)
6. Bowen NJ, Fujita N, KajitaM& Wade PA 2004 Mi-2/NuRD: multiple complexes for many purposes. Biochimica et Biophysica Acta 1677 52-57.
7. Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Janicke F, Muller V, Bokemeyer C, Simon R, Sauter G et al. 2010 Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment 123 757-765. (doi:10.1007/s10549-009-0675-8)
8. Carter CL, Corle DK, Micozzi MS, Schatzkin A & Taylor PR 1988 A prospective study of the development of breast cancer in 16,692 women with benign breast disease. American Journal of Epidemiology 128 467-477.
9. Chen Y & Olopade OI 2008 MYC in breast tumor progression. Expert Review of Anticancer Therapy 8 1689-1698. (doi:10.1586/14737140.8.10.1689)
10. Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM & Hwang ES 2009 Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 9 285. (doi:10.1186/1471-2407-9-285)
11. Creekmore AL, Walt KA, Schultz-Norton JR, Ziegler YS, McLeod IX, Yates JR & Nardulli AM 2008 The role of retinoblastoma-associated proteins 46 and 48 in estrogen receptor alpha mediated gene expression. Molecular and Cellular Endocrinology 291 79-86. (doi:10.1016/j.mce.2008.05.016)
12. Cuzick J 2003 Treatment of DCIS - results from clinical trials. Surgical Oncology 12 213-219. (doi:10.1016/j.suronc.2003.09.001)
13. Deisenroth C, Thorner AR, Enomoto T, Perou CM & Zhang Y 2010 Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Molecular and Cellular Biology 30 3981-3993. (doi:10.1128/MCB.01284-09)
14. van Diest PJ, van der Wall E & Baak JP 2004 Prognostic value of proliferation in invasive breast cancer: a review. Journal of Clinical Pathology 57 675-681. (doi:10.1136/jcp.2003.010777)
15. Done SJ, Arneson NC, Ozcelik H, Redston M & Andrulis IL 1998 p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Research 58 785-789.
16. Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM, Barry SC, Ramsay RG & Gonda TJ 2007 Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. PNAS 104 13762-13767. (doi:10.1073/pnas.0700104104)
17. Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, Sastre-Garau X, Kaaks R, Bussolati G, Pisani P, Tavassoli FA, et al. 2003 Invasive breast carcinoma. In World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Breast and Female GenitalOrgans, pp 13-59. Eds FA Tavassoli & P Devilee. Lyon, France: IARC Press.
18. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR & Katzenellenbogen BS 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 4562-4574. (doi:10.1210/en.2003-0567)
19. Gerdes J, Schwab U, Lemke H & Stein H 1983 Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. International Journal of Cancer 31 13-20. (doi:10.1002/ijc. 2910310104)
20. van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG & van der Wall E 2009 Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. Journal of Clinical Pathology 62 926-930. (doi:10.1136/jcp.2009.065524)
21. Guan LS, Rauchman M & Wang ZY 1998 Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition. Journal of Biological Chemistry 273 27047-27050. (doi:10.1074/jbc.273.42.27047)
22. Guerin M, Sheng ZM, Andrieu N & Riou G 1990 Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 5 131-135.
23. Half E, Tang XM, Gwyn K, Sahin A, Wathen K & Sinicrope FA 2002 Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Research 62 1676-1681.
24. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al. 2010 American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology 28 2784-2795. (doi:10.1200/JCO.2009.25. 6529)
25. Han CH, Wei Q, Lu KK, Liu Z, Mills GB & Wang LE 2009 Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. International Journal of Clinical and Experimental Medicine 2 289-299.
26. Hinnis AR, Luckett JC & Walker RA 2007 Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. British Journal of Cancer 96 639-645. (doi:10.1038/sj.bjc.6603616)
27. Hwang ES, DeVries S, Chew KL, Moore DH II, Kerlikowske K, Thor A, Ljung BM & Waldman FM 2004 Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clinical Cancer Research 10 5160-5167. (doi:10.1158/1078- 0432.CCR-04-0165)
28. Irvine T & Fentiman IS 2007 Biology and treatment of ductal carcinoma in situ. Expert Review of Anticancer Therapy 7 135-145. (doi:10.1586/14737140. 7.2.135)
29. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R & Clynes M 2003 Prognostic importance of survivin in breast cancer. British Journal of Cancer 88 1077-1083. (doi:10.1038/sj.bjc.6600776)
30. Kepple J, Henry-Tillman RS, Klimberg VS, Layeeque R, Siegel E, Westbrook K & Korourian S 2006 The receptor expression pattern in ductal carcinoma in situ predicts recurrence. American Journal of Surgery 192 68-71. (doi:10.1016/j.amjsurg.2006.04.002)
31. Klebig C, Korinth D & Meraldi P 2009 Bub1 regulates chromosome segregation in a kinetochore-independent manner. Journal of Cell Biology 185 841-858. (doi:10.1083/jcb.200902128)
32. Kleinberg L, Florenes VA, Nesland JM & Davidson B 2007 Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. American Journal of Clinical Pathology 128 389-397. (doi:10.1309/E899BG1282M5D505)
33. Lakhani SR, Chaggar R, Davies S, Jones C, Collins N, Odel C, Stratton MR & O'Hare MJ 1999 Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. Journal of Pathology 189 496-503. (doi:10.1002/(SICI)1096- 9896(199912)189:4〈496::AID-PATH485〉3.0.CO;2-D)
34. Li CI, Daling JR & Malone KE 2005 Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiology Biomarkers & Prevention 14 1008-1011. (doi:10.1158/1055-9965.EPI-04-0849)
35. McCarty KS Jr, Miller LS, Cox EB, Konrath J & McCarty KS Sr 1985 Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archives of Pathology & Laboratory Medicine 109 716-721.
36. McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA & Clevenger CV 2008 Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Modern Pathology 21 565-571.
37. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H & Badve S 2012 FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Research and Treatment 131 881-890. (doi:10.1007/s10549-011-1482-6)
38. Nofech-Mozes S, Spayne J, Rakovitch E & Hanna W 2005 Prognostic and predictive molecular markers in DCIS: a review. Advances in Anatomic Pathology 12 256-264. (doi:10.1097/01.pap.0000184177.65919.5e)
39. Oh IH & Reddy EP 1999 The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18 3017-3033. (doi:10.1038/sj.onc. 1202839)
40. Okumura Y, Yamamoto Y, Zhang Z, Toyama T, Kawasoe T, Ibusuki M, Honda Y, Iyama K, Yamashita H & Iwase H 2008 Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. BMC Cancer 8 287. (doi:10.1186/1471-2407-8-287)
41. Park K, Han S, Kim HJ, Kim J & Shin E 2006 HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridisation and immunohistochemistry. Histopathology 48 702-707. (doi:10.1111/j.1365-2559.2006. 02403.x)
42. Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof PM, Peterse JL & van de Vijver MJ 2003 Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. Journal of Pathology 201 75-82. (doi:10.1002/path.1385)
43. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ et al. 2006 Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Annals of Oncology 17 597-604. (doi:10.1093/annonc/mdj121)
44. Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB et al. 2008 Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocrine-Related Cancer 15 113-124. (doi:10.1677/ERC-07- 0092)
45. Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS & Kim TY 2006 Expression of survivin and clinical correlation in patients with breast cancer. Biomedicine & Pharmacotherapy 60 289-292. (doi:10.1016/j.biopha.2006.06.008)
46. Sontag L & Axelrod DE 2005 Evaluation of pathways for progression of heterogeneous breast tumors. Journal of Theoretical Biology 232 179-189. (doi:10.1016/j.jtbi.2004.08.002)
47. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S & Sasano H 2007 Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Endocrine-Related Cancer 14 279-292. (doi:10.1677/ERC-06- 0005)
48. Suzuki S, Takagi K, Miki Y, Onodera Y, Akahira JI, Ebata A, Ishida T, Watanabe M, Sasano H & Suzuki T 2012 Nucleobindin 2 (NUCB2) in human breast carcinoma as a potent prognostic factor. Cancer Science 103 136-143. (doi:10.1111/j.1349-7006.2011.02119.x)
49. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M & Tanigawa N 2000 Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clinical Cancer Research 6 127-134.
50. Thorner AR, Parker JS, Hoadley KA & Perou CM 2010 Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS ONE 5 e13073. (doi:10.1371/journal.pone.0013073)
51. Tsikitis VL & Chung MA 2006 Biology of ductal carcinoma in situ classification based on biologic potential. American Journal of Clinical Oncology 29 305-310. (doi:10.1097/01.coc.0000198740.33617.2f)
52. Wiechmann L & Kuerer HM 2008 The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 112 2130-2142. (doi:10.1002/cncr.23430)
53. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 25 118-145. (doi:10.1200/JCO.2006.09.2775)
54. Xu Y, Fang F, Ludewig G, Jones G & Jones D 2004 A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA and Cell Biology 23 527-537.
55. Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P & Reinberg D 1997 Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell 89 357-364. (doi:10.1016/S0092-8674(00)80216-0)
56. Zhang TF, Yu SQ & Wang ZY 2007 RbAp46 inhibits estrogen-stimulated progression of neoplastigenic breast epithelial cells. Anticancer Research 27 3205-3209.
57. Zhang J, Luo N, Luo Y, Peng Z, Zhang T & Li S 2012 microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. International Journal of Oncology 40 747-756. (doi:10.3892/ijo.2011.1242)